Paolo Tarantino (@PTarantinoMD) header
Paolo Tarantino (@PTarantinoMD) profile picture

MD, PhD, Medical Oncologist | Clinical Fellow @DanaFarber | @Harvard. Associate Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs and good music.

Boston, MA
Joined January 2018
Photo by Paolo Tarantino (@PTarantinoMD)Photo by Paolo Tarantino (@PTarantinoMD)Photo by Paolo Tarantino (@PTarantinoMD)Photo by Paolo Tarantino (@PTarantinoMD)Photo by Paolo Tarantino (@PTarantinoMD)Photo by Paolo Tarantino (@PTarantinoMD)Photo by Paolo Tarantino (@PTarantinoMD)Photo by Paolo Tarantino (@PTarantinoMD)
ADCs enable an improved delivery of chemo, expanding its activity, but not necessarily decreasing its side effects. Why is that? How can we reduce the toxicities of ADCs? Glad to share our @NatRevClinOncol article on how to optimize the safety of ADC! 🧵 nature.com/articles/s41571-0… – at Boston, MA
18
127
6
388
117,846
Excellent review of established ADCs and upcoming bispecific antibody constructs by @dradityabardia at #ENASymp26.
6
437
Paolo Tarantino retweeted
🚨Novel ADC at EORTC–NCI–AACR #ENA2026 Micvotabart pelidotin targets EDB-fibronectin in the tumour extracellular matrix Phase I in R/M head &neck squamous cell carcinoma n=33 📊ORR 39% 📈Median PFS 6.7 months; Phase III planned @PTarantinoMD @curijoey event.eortc.org/ena2026/2026…
4
3
225
Most ADCs deliver cytotoxic payloads, with substantial cross-resistance (e.g., TOP1i). But a new generation of ADCs delivering targeted therapies may expand our arsenal, with KRASi & PI3Ki ADCs in pole position, soon in clinical development. Great talk by @raffcolo at #ENASymp26!
1
9
16
1,489
Excellent overview of degrader-antibody conjugates (DACs) by Nicole Biber. #ENASymp26
3
7
851
Paolo Tarantino retweeted
Wonderful data from Adcendo. Really happy to see this presented in Barcelona, of all places Soft tissue sarcoma is one of those indications that is considered a graveyard for drug development… until it isn’t
After taking over epithelial tumors, ADCs are coming for treating sarcomas! Encouraging phase 1 data with the uPARAP-directed ADC ADCE-D01, with 30% ORR across multiple types of sarcoma. Key tox: neutropenia (requiring growth factors), nausea, IRR. #ENA26
4
8
478
Paolo Tarantino retweeted
News from #ENASymp26: Antibody-drug conjugate designed to target tumour ‘scaffolding’ produces positive results in phase I head and neck cancer trial: ow.ly/c3b85107Yo7
3
1
247
Paolo Tarantino retweeted
News from #ENASymp26: Antibody-drug conjugate shows promising early results in phase I trial in sarcoma patients: ow.ly/CrZQ5107YmF New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancer: ow.ly/8WPZ5107YmE
3
1
241
Impressive phase 1 data with REM-422, a MYB mRNA degrader, among patients with (mostly) salivary gland ACC: ORR 42% in biomarker positive tumors, PFS approaching 2 years, extremely clean toxicity profile. And fascinating mechanism of action! #ENA26
2
1
14
1,142
After taking over epithelial tumors, ADCs are coming for treating sarcomas! Encouraging phase 1 data with the uPARAP-directed ADC ADCE-D01, with 30% ORR across multiple types of sarcoma. Key tox: neutropenia (requiring growth factors), nausea, IRR. #ENA26
5
2
38
2,452
I strongly support Dr. Pal. Few have contributed so much to the oncology community.
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
2
9
22
1,524
Promising phase 1 data with the tumor microenvironment-directed ADC micvotabart pelidotin (PYX-201) in HNSCC: ORR 39%, mPFS 6.7 months, typical auristatin payload tox. No correlation between efficacy and target expression. Breast cancer cohort open at @DFCI_BreastOnc. #ENA26
2
3
492
Pre-session briefing with @raffcolo ahead of today’s #ENA26 Triple meeting Plenary Session on ADCs! Looking forward to discussing the latest advances in the field alongside @dradityabardia, #AlexSpira, and #NicoleBiber. @theNCI @AACR @eortc
1
8
629
Paolo Tarantino retweeted
And we’re just getting started….
Tuesday was the first day in OpenEvidence history with more than two million consults from verified U.S. clinicians in one 24-hour cycle. About one consult for every two physician office visits in America. The math: Americans make over a billion visits to physicians’ offices a year, roughly four million on a typical weekday. A consult is not a visit, and one visit can involve several questions. OpenEvidence is unequivocally the most popular AI for doctors in the United States and has become the default operating system of medical knowledge.
3
3
15
1,013
Paolo Tarantino retweeted
Neoadjuvant immunotherapy is safe and effective in resectable HCC - a 10 years adventure comes to an end today to dictate new beginnings for the benefit of our patients @A_DAlessioMD @imperialcollege @ECMC_UK
🔴Online now: Neoadjuvant nivolumab + ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a phase 1b trial 📈Article: thelancet.com/journals/lanon… @A_DAlessioMD, @DJPinato & colleagues ✏️Comment: thelancet.com/journals/lanon…
5
15
794
Paolo Tarantino retweeted
Did you know that STOP-HER2 is a #TBCRC trial? This phase 2 study is the first prospective trial to evaluate whether HER2 blockade can be safely discontinued in exceptional responders with HER2+ metastatic BC. Results at #SABCS26 will be critical! 👉Follow @TheTBCRC for more!
The phase II STOP-HER2 trial followed patients with HER2-positive metastatic breast cancer who stopped trastuzumab after a sustained response. Heather Parsons, MD, MPH, presents December 11 at #SABCS26. bit.ly/4kNbpDi
10
1
39
2,883
Paolo Tarantino retweeted
One evening. One community. Countless connections ✨ Join colleagues from around the world at the #SGBCC2027 Conference Evening at the iconic MAK in Vienna. #ConferenceEvening #Vienna #BreastCancerCommunity
1
2
247
Paolo Tarantino retweeted
For physicians caring for patients with ovarian cancer, a request from the wonderful @DrKatyMoore on behalf of the Lancet Commission to complete a survey. QR code & link in her post. And pls share widely. @oncodaily @OncLive @PTarantinoMD @montypal @NarjustFlorezMD @lungoncdoc
Hi all - another plea on behalf of the Lancet Commission on Ovarian Cancer. We are trying to maximize responses to the physician questionnaire - I know it is long (sry) but would so appreciate as many of you as possible participating. The QR code is here for you to scan or can hit this link. If you care for women with ovarian cancer we would love your input. redcap.sydney.edu.au/surveys… thanks so much
1
287
Paolo Tarantino retweeted
STOPHER2 is TBCRC 062. This means SIXTY ONE trials before and many more after all changing how we understand, manage and redefine breast cancer care. Amazing work by @hthrparsons and @TheTBCRC
Did you know that STOP-HER2 is a #TBCRC trial? This phase 2 study is the first prospective trial to evaluate whether HER2 blockade can be safely discontinued in exceptional responders with HER2+ metastatic BC. Results at #SABCS26 will be critical! 👉Follow @TheTBCRC for more!
2
3
504